Although many of these therapies, such as bevacizumab (anti-VEGF-A), are being used in combination with other therapeutic modalities, such as chemotherapy and endocrine therapy [26], studies are ongoing to find the optimal method to elucidate tumor response and overcome therapeutic resistance to antiangiogenic treatments. The gene discussed is VEGFA; the disease is neoplasm.